2016 FDA Approved Drugs
The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale
in the United States. Drug information typically includes the drug name, approval status, indication of use, and
clinical trial results.
Review descriptions for our medical therapeutic area list to help
assist in your search.
Join our Drug Research Updates group on LinkedIn!
about the types of drugs included in this listing.
Cardiology/Vascular Diseases
Byvalson (nebivolol and valsartan); Allergan;
For the treatment of hypertension, Approved June 2016
Dermatology
Ameluz (aminolevulinic acid hydrochloride); Biofrontera Pharma;
For the treatment of actinic keratoses, Approved May 2016
Taltz (ixekizumab); Eli Lilly;
For the treatment of plaque psoriasis, Approved March 2016
Endocrinology
Adlyxin (lixisenatide); Sanofi Aventis;
For the treatment of type II diabetes, Approved July 2016
Family Medicine
Byvalson (nebivolol and valsartan); Allergan;
For the treatment of hypertension, Approved June 2016
Onzetra Xsail (sumatriptan nasal powder) ; Avanir;
For the treatment of migraine, Approved January 2016
Hematology
Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring;
For the treatment of hemophillia A, Approved May 2016
Idelvion (Coagulation Factor IX (Recombinant), Albumin Fusion Protein); CSL Behring;
For the treatment of hemophilia B, Approved March 2016
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ;
For the treatment of hemophillia A, Approved March 2016
Opdivo (nivolumab); Bristol-Myers Squibb;
For the treatment of classical Hodgkin lymphoma, Approved May 2016
Venclexta (venetoclax); AbbVie;
For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016
Hepatology (Liver, Pancreatic, Gall Bladder)
Defitelio (defibrotide sodium); Jazz Pharmaceuticals;
For the treatment of hepatic veno-occlusive disease with renal or pulmonary dysfunction following HSCT, Approved March 2016
Ocaliva (obeticholic acid); Intercept Pharmaceuticals;
For the treatment of primary biliary cholangitis, Approved May 2016
Zepatier (elbasvir and grazoprevir); Merck;
For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016
Immunology
Afstyla (Antihemophilic Factor (Recombinant), Single Chain); CSL Behring;
For the treatment of hemophillia A, Approved May 2016
Descovy (emtricitabine and tenofovir alafenamide); Gilead;
For the treatment of HIV-1 infection, Approved April 2016
Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences;
For the treatment of hepatitis C, Approved June 2016
Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences;
For the treatment of HIV-1 as initial therapy, Approved March 2016
Taltz (ixekizumab); Eli Lilly;
For the treatment of plaque psoriasis, Approved March 2016
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax;
For active immunization against Cholera, Approved June 2016
Infections and Infectious Diseases
Anthim (obiltoxaximab); Elusys Therapeutics;
For the treatment of inhalational anthrax , Approved March 2016
Descovy (emtricitabine and tenofovir alafenamide); Gilead;
For the treatment of HIV-1 infection, Approved April 2016
Epclusa (sofosbuvir and velpatasvir) ; Gilead Sciences;
For the treatment of hepatitis C, Approved June 2016
Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide); Gilead Sciences;
For the treatment of HIV-1 as initial therapy, Approved March 2016
Syndros (dronabinol oral solution); Insys Therapeutics;
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax;
For active immunization against Cholera, Approved June 2016
Zepatier (elbasvir and grazoprevir); Merck;
For the treatment of chronic HCV genotypes 1 or 4 , Approved January 2016
Musculoskeletal
Zinbryta (daclizumab) ; Biogen;
For the treatment of relapsing multiple sclerosis, Approved May 2016
Nephrology
Cabometyx (cabozantinib); Exelixis;
For the treatment of advanced renal cell carcinoma, Approved April 2016
Lenvima (lenvatinib); Eisai;
For the treatment of advanced renal cell carcinoma, Approved May 2016
Rayaldee (calcifediol) ; Opko Health;
For the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, Approved June 2016
Neurology
Briviact (brivaracetam); UCB;
For the treatment of partial onset seizures related to epilepsy, Approved February 2016
Nuplazid (pimavanserin); Acadia Pharmaceuticals;
For the treatment of hallucinations and delusions associated with Parkinson’s disease, Approved April 2016
Nuplazid (pimavanserin); Acadia Pharmaceuticals;
For the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, Approved May 2016
Onzetra Xsail (sumatriptan nasal powder) ; Avanir;
For the treatment of migraine, Approved January 2016
Troxyca ER (oxycodone + naltrexone); Pfizer;
For the management of severe pain, Approved August 2016
Zinbryta (daclizumab) ; Biogen;
For the treatment of relapsing multiple sclerosis, Approved May 2016
Oncology
Cabometyx (cabozantinib); Exelixis;
For the treatment of advanced renal cell carcinoma, Approved April 2016
Keytruda (pembrolizumab); Merck;
For the treatment of head and neck squamous cell cancer , Approved August 2016
Lenvima (lenvatinib); Eisai;
For the treatment of advanced renal cell carcinoma, Approved May 2016
Opdivo (nivolumab); Bristol-Myers Squibb;
For the treatment of classical Hodgkin lymphoma, Approved May 2016
Sustol (granisetron); Heron Therapeutics;
For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016
Syndros (dronabinol oral solution); Insys Therapeutics;
For the treatment of anorexia associated with AIDS and nausea and vomiting associated with cancer chemotherapy, Approved July 2016
Tecentriq (atezolizumab); Genentech;
For the treatment of urothelial carcinoma, Approved May 2016
Venclexta (venetoclax); AbbVie;
For the treatment of chronic lymphocytic leukemia with 17p deletion, Approved April 2016
Ophthalmology
Humira (adalimumab); Abbvie;
For the treatment of uveitis, Approved July 2016
Xiidra (lifitegrast); Shire;
For the treatment of dry eye disease, Approved July 2016
Pediatrics/Neonatology
Kovaltry [Antihemophilic Factor (Recombinant)]; Bayer ;
For the treatment of hemophillia A, Approved March 2016
Pharmacology/Toxicology
Sustol (granisetron); Heron Therapeutics;
For the prevention of chemotherapy-induced nausea and vomiting, Approved August 2016
Psychiatry/Psychology
Nuplazid (pimavanserin); Acadia Pharmaceuticals;
For the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, Approved May 2016
Pulmonary/Respiratory Diseases
Bevespi Aerosphere (glycopyrrolate and formoterol fumarate); AstraZeneca;
For the treatment of chronic obstructive pulmonary disease, Approved April 2016
Cinqair (reslizumab); Teva Pharmaceuticals;
For the treatment of severe asthma, Approved March 2016
Urology
Tecentriq (atezolizumab); Genentech;
For the treatment of urothelial carcinoma, Approved May 2016
Vaccines
Vaxchora (Cholera Vaccine, Live, Oral); PaxVax;
For active immunization against Cholera, Approved June 2016
